Evaluation of Tolerance and Pharmacokinetic Profile of High Doses of Favipiravir in Healthy Volunteers

Infectious Disease Clinical Trial

— FAVIDOSE  

Official title:

EVALUATION DE LA TOLERANCE ET DU PROFIL PHARMACOCINETIQUE DE DOSES ELEVEES DE FAVIPIRAVIR CHEZ LE VOLONTAIRE SAIN

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06024421
• Other study ID #: C18-47
• Secondary ID: 2022-502871-49-0
• Status: Recruiting
• Phase: Phase 1
• Start date: May 14, 2024
• Est. completion date: November 2027

Study information

• Verified date: May 2024
• Source: Institut National de la Santé Et de la Recherche Médicale, France
• Contact: France MENTRE
• Phone: +33 1 40 25 79 31
• Email: france.mentre[@]inserm.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

FAVIDOSE trial is a Phase I randomized, double blind controlled, monocentric, dose escalation clinical trial. The primary purpose of this trial is to evaluate tolerance of high doses of favipiravir for 14 days in healthy volunteers. This trial also looks to characterize favipiravir pharmacokinetics in blood and favipiravir levels in sperm. A pharmacogenetics analysis will be conducted in an attempt to identify genetic variants of metabolism and transport enzymes of favipiravir to explain the inter-individual variability of pharmacokinetic parameters of favipiravir.

Three sequential dose levels including distinctive participants:

• level 1: D1: 2400 mg BID; D2 to D13: 1600 mg BID and D14: 1600 mg in the morning;

• level 2: D1: 2400 mg BID; D2 to D13: 2000 mg BID and D14: 2000 mg in the morning;

• level 3: D1: 2400 mg BID; D2 to D13: 2400 mg BID andD14: 2400 mg in the morning.

Three study groups of maximum of 8 participants, 6 receiving favipiravir and 2 receiving placebo per dose level, three dose levels proposed. Seven additional participants with the same follow up will be included and randomized (6:1 ratio) at the maximum tolerated dose level to allow a satisfactory accurate characterization of pharmacokinetics and pharmacogenetics of favipiravir and their determinants (maximum 39 participants in total, taking into account 8 participants - 2 per dose level - replaced because loss of follow-up before the end of treatment).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 39
• Est. completion date: November 2027
• Est. primary completion date: June 2027
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Man between 50 and 75 years old without any desire to have children or woman between 18 and 75 years old ;

2. Subject considered healthy after a thorough general examination (questioning, physical examination);

3. For men: acceptance of semen collection by masturbation;

4. For men: acceptance of condom use from initiation of the investigational drug until 1 month after stopping the investigational drug;

5. For women of childbearing potential: effective contraceptive method combining two methods of contraception (one female contraceptive method combined with male condom use) from the inclusion visit until 1 month after discontinuation of the investigational drug;

6. Blood chemistry:

• Kalemia, Calcemia, Prothrombin rate (PT), Activated partial thromboplastin time (APTT): values within laboratory normal;

• ALT, ASAT, Uricemia: values below the upper limit of the laboratory normal;

• Other biological results (Blood count; Natremia; Phosphoremia; Chloremia; Fasting blood glucose; Gamma glutamyl transpeptidase; Urea; Total bilirubin; Creatinine; CPK; Lactate dehydrogenase; Albuminemia; Proteinemia; Triglycerides; C-reactive protein; Albumin/Globulin ratio; Alkaline phosphatase) with no clinically significant abnormality.

NB: A parameter outside the usual values considered clinically significant may, at the investigator's discretion, be tested a second time on another sample taken outside of a visit planned in the protocol before the initiation of the experimental drug.

7. Urine dipstick (biochemistry: leukocyturia, proteinuria and hematuria) without clinically significant abnormality;

8. Urine tox screen negative (amphetamines/metamphetamines, barbiturates, benzodiazepines, cannabis, cocaine, opiates);

9. Ability to take the investigational drug orally and adherence to the dosage of the investigational drug;

10. Acceptance and signing of the informed consent;

11. Membership in a social security plan or beneficiary of such a plan;

12. Adherence to lifestyle considerations (see section 5.5) during participation in this research.

Exclusion Criteria:

1. Concomitant use or within 15 days prior to inclusion of another QT/QTc prolonging drug or drugs that may disrupt electrolyte levels, among others: loop diuretics, thiazide diuretics and related drugs (see list www.crediblemeds.org)

2. History of amiodarone use within 6 months prior to inclusion

3. History of gout or current treatment for gout or hyperuricemia

4. Treatment with pyrazinamide or any other drug known to induce hyperuricemia

5. History of hypersensitivity reaction to a nucleoside analog targeting viral RNA polymerase

6. Known hypersensitivity to any of the components (favipiravir or placebo)

7. Pregnant or breastfeeding women

8. For men: history of vasectomy or known history of infertility.

9. Refusal of the subject to complete all the visits, clinical and paraclinical examinations planned by the study

10. On ECG: PR >200ms, QRS >100ms QTc >450ms and morphological appearance of abnormal repolarization

11. PAS <100 mmHg

12. Any history or active cardiovascular, pulmonary, intestinal, hepatic, renal, metabolic, hematologic, neurologic, bone, joint, muscular, psychiatric, systemic, ocular, gynecologic, andrologic, or infectious disease (including active HIV, HCV, or HBV infection), or any acute condition, which in the judgment of the investigator could be detrimental to the volunteer and/or interfere with or limit the protocol evaluation and data analysis

13. Personal or family history of long QT syndrome, torsades de pointes or sudden death

14. Patient with severe hepatic impairment

15. Gastrointestinal pathology such as ileus, colitis or enterocolitis

16. Treatment with another investigational drug or other investigational procedure (clinical trial, clinical investigation of a medical device, category 1 or 2 research involving humans);

17. A person who is subject to a legal protection measure (safeguard of justice, curatorship, guardianship);

18. Person placed in administrative detention;

19. Person who, in the judgment of the investigating physician, may be non-observant during the study, or unable to communicate due to a language barrier or mental disorder

20. Person who cannot be contacted in an emergency

21. Person with at least one first-degree relative from East Asia or Southeast Asia.

Secondary Exclusion Criteria

Participants with at least one of the following criteria will not start the experimental treatment at D1 if they are already randomized:

1. Positive nasopharyngeal antigen test for SARS-CoV-2 at D1 (prior to treatment initiation)

2. Blood potassium levels outside the normal laboratory range within 8 days prior to treatment initiation (D1)

3. ECG: PR >200ms, QRS >100ms QTc >450ms and morphological appearance of abnormal repolarization on Day 1

4. Positive pregnancy test on Day 1 (before initiation of treatment)

Related Conditions & MeSH terms

• Communicable Diseases
• Infections
• Infectious Disease
• Pharmacology

Intervention

Drug:
• favipiravir
Light yellow, film-coated tablet, each containing 200 mg of favipiravir
• Placebo
Light yellow, film-coated tablet

Locations

Country	Name	City	State
France	University Hospital Bichat - Claude Bernard	Paris

Sponsors (2)

Lead Sponsor	Collaborator
Institut National de la Santé Et de la Recherche Médicale, France	FUJIFILM Toyama Chemical Co., Ltd.

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Tolerance	Tolerance of high doses of favipiravir, defined by the number of participants with at least one adverse medical event considered as related to favipiravir (AER)-as determined and validated by the sponsor- clinical stage 3 or 4 according to the CTCAE (v5.0) not found at inclusion at same level and biological AER de stage 3 or 4 not found at inclusion in the same level. AER are collected daily until D15 and at D21 and D28, as well as at M3 and M6 for participating men.; D1 is the first day of favipiravir or placebo intake.	Months 6
Secondary	Plasma concentration of favipiravir	Construction of the pharmacokinetic model and the estimation of its parameters will be realized by a population pharmacokinetic analysis integrating all available data on plasma concentration.	Day 1 (Hour 0; Hour 0.5 ; Hour 1; Hour 2; Hour 5; Hour 8), Day 3 (Hour 0 ; Hour 0.5; Hour 2), Day 7 (Hour 0; Hour 0.5 ; Hour 1; Hour 2; Hour 5; Hour 8), Day 10 (Hour 0), Day 14 (Hour 0; Hour 0.5 ; Hour 1; Hour 2; Hour 5; Hour 8), Day 15 (Hour 0)
Secondary	Genetic	Genetic variants associated with favipiravir exposure. Targeted genotyping of variants of the gene encoding the enzyme responsible for transport and metabolism of favipiravir (aldehyde deshydrogenase) will be performed.	Days 1
Secondary	Sperm pharmacology	For participating men: favipiravir concentration in sperm at D14 and D28.	Day 14, day 28